Wave Life Sciences (WVE) Net Equity Issued and Repurchased (2015 - 2025)

Wave Life Sciences' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $330.9 million for Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 290.29% year-over-year to $330.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $330.9 million (up 2257.26% YoY) and the FY2025 annual result came in at $330.9 million, up 2257.26% from the prior year.
• Net Equity Issued and Repurchased was $330.9 million for Q4 2025 at Wave Life Sciences, up from -$173.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $330.9 million in Q4 2025 and bottomed at -$173.9 million in Q4 2024.
• A 5-year average of $41.9 million and a median of $8.1 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased soared 623926.67% — and 2024, when it slumped 285.84%.
• Wave Life Sciences' Net Equity Issued and Repurchased stood at $33.8 million in 2021, then slumped by 100.04% to -$15000.0 in 2022, then surged by 623926.67% to $93.6 million in 2023, then slumped by 285.84% to -$173.9 million in 2024, then surged by 290.29% to $330.9 million in 2025.
• Business Quant data shows WVE's Net Equity Issued and Repurchased at $330.9 million in Q4 2025, -$173.9 million in Q4 2024, and $173.9 million in Q3 2024.